RxDoctor Payments Data

Christina Bowens, APRN

Nurse Practitioner · Tampa, FLNPI 1053989574

Payments from drug & device makers

$483in general payments, 2019–2025

Across 22 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$181
  • Boehringer Ingelheim$73
  • Lilly USA, LLC$67
  • Pfizer$50
  • Novo Nordisk$43
  • AstraZeneca$36
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK7$181
Boehringer Ingelheim3$73
Lilly USA, LLC3$67
Pfizer3$50
Novo Nordisk2$43
AstraZeneca2$36
Johnson & Johnson1$20
Vistapharm, Inc.1$13

How this compares

$483 in reported general payments places this provider in the 60th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$12,579
Medicare patients
110
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,739
EliquisApixaban13$17,960
MounjaroTirzepatide15$17,749
OzempicSemaglutide11$11,734
Spiriva HandihalerTiotropium Bromide14$7,607
Advair HfaFluticasone Propion/Salmeterol11$3,534
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,284
PaxlovidNirmatrelvir/Ritonavir34$2,859
Albuterol Sulfate HfaAlbuterol Sulfate84$2,440
Atorvastatin Calcium206$1,536
Nifedipine ErNifedipine18$944
Duloxetine Hcl18$873
Rosuvastatin Calcium84$864
Lisinopril153$851
Losartan Potassium85$821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$50$20,81947 claims
GSKTrelegy Ellipta$181$19,73925 claims
Lilly USA, LLCMounjaro$67$17,74915 claims
Novo NordiskOzempic$43$11,73411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →